Here's Why Nyxoah (NYXH) Could be Great Choice for a Bottom FisherZacks Investment Research · 4 days ago
Nyxoah Announces Preliminary Results for the Third Quarter of 2026 and Adjusts Revenue Guidance for 2026GlobeNewsWire · 5 days ago
Contrasting Nephros (NASDAQ:NEPH) & Nyxoah (NASDAQ:NYXH)Defense World · Oct 13, 2026
Nyxoah: Label Expansion Set To Unlock A Monopoly In A Billion Dollar Market.Seeking Alpha · Oct 5, 2026
Nyxoah Appoints Liam Kelly as Chief Executive OfficerGlobeNewsWire · Sep 28, 2026
Nyxoah Announces Chief Financial Officer TransitionGlobeNewsWire · Sep 21, 2026Nyxoah SA, a medical technology company, develops and commercializes solutions to treat obstructive sleep apnea (OSA). The company’s lead solution comprises Genio system, a CE-Marked, patient-centric, minimally invasive, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea. Nyxoah SA was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgium.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 5, 2026 | -$0.47 | -$0.67 | Miss |
| May 12, 2026 | -$0.54 | -$0.43 | Beat |
| Mar 19, 2026 | -$0.65 | -$0.68 | Miss |
| Nov 13, 2025 | -$0.61 | -$0.74 | Miss |
| Aug 18, 2025 | -$0.62 | -$0.63 | Miss |
| May 14, 2025 | -$0.49 | -$0.63 | Miss |